Novartis
Top Ten most popular articles on Pharmafile.com this week
May 11, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, GSK, J&J, JJ, Novartis, Shire, Takeda, Valeant, biotech, drugs, pharma, pharmaceutical
It’s been a week in which one of the largest pharmaceutical takeovers in history took place and yet it’s not …
Novartis’ $1.2m payment to Trump’s lawyer raises more questions than answers
May 10, 2018Medical Communications Essential Consultants, Michael Cohen, Novartis, President trump, Trump, biotech, drugs, pharma, pharmaceutical
Novartis payment to President Trump’s personal lawyer, Michael Cohen, had seemed fairly odd from the beginning – with many asking …
Novartis caught in the Stormy Daniels affair, after huge payment to Trump’s lawyer
May 9, 2018Medical Communications, Research and Development Cohen, Novartis, President trump, Trump, biotech, drugs, pharma, pharmaceutical
Novartis has suddenly found itself embroiled in the Stormy Daniels affair, after the lawyer representing her, Michael Avenatti, included the …
Top Ten most popular articles on Pharmafile.com this week
May 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia
It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …
Sandoz US woes continue with biosimilar rejection
May 3, 2018Sales and Marketing Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical
In Novartis’ recently released Q1 results, which largely beat analysts’ estimates, Sandoz was a black spot on its record – …
Novartis becomes first to gain second CAR T indication
May 2, 2018Research and Development, Sales and Marketing Gilead, Kymriah, Novartis, Yescarta, biotech, drugs, pharma, pharmaceutical
Novartis has announced that its CAR T treatment, Kymriah, has successfully been given a second indication for the treatment of …
Novartis forges forward into digital pharma with FocalView app
April 25, 2018Medical Communications, Research and Development FocalView, Novartis, biotech, drugs, pharma, pharmaceutical
There is a growing trend in big pharma to talk up the potential for digital technology to revolutionise operations and …
Novartis expands Pear partnership to tackle opioid and substance use disorder
April 23, 2018Research and Development, Sales and Marketing Novartis, Pear Therapeutics, Sandoz, opioids, pharma, substance use disorder
Novartis has announced that it will expand its current partnership with Pear Therapeutics, signed in March, as it reveals that …
Top Ten most popular articles on Pharmafile.com this week
April 20, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical
It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …
Novartis snatches Amgen and BMS veteran for CMO and Drug Development Head
April 19, 2018Medical Communications Amgen, BMS, Bristol-Myers Squibb, Novartis, appointment, pharma
Dr John Tsai has been welcomed to the fold as Novartis’ new Head of Global Development and Chief Medical Officer, …
Amgen and Novartis’ Aimovig shines in migraine at Phase 3
April 18, 2018Research and Development Aimovig, Amgen, Novartis, migraine, pharma
Amgen has lifted the curtain on complete Phase 3 data for its calcitonin gene-related peptide receptor (CGRP) inhibitor Aimovig (erenumab) in …
Novartis to invest $100m in new malaria treatments
April 17, 2018Manufacturing and Production, Research and Development Novartis, WHO, malaria, pharma
Novartis has revealed it is to invest $100 million into the research and development of new treatments for malaria over …
Novartis’ Entresto helps preserve kidney function in chronic heart failure patients
April 16, 2018Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma
Novartis has lifted the curtain on new data from a Phase 3 trial investigating the efficacy of Entresto (sacubitril/valsartan) in …
Top Ten most popular articles on Pharmafile.com this week
April 13, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Cancer, Humira, Mylan, Novartis, Shire, Takeda, Teva, acquisition, cystic fibrosis, hepatitis C, pharma, top ten
It’s Friday the 13th, but that doesn’t change a strong showing from the industry this week as it continued to …
Novartis CEO makes mark with $8.7bn AveXis acquisition
April 9, 2018Sales and Marketing AveXis, Novartis, biotech, drugs, gene therapy, pharma, pharmaceutical
Vas Narasimhan’s first few moves as CEO of Novartis indicate that he is not afraid to take bold risks in …
Latest content
FibroFind appoints Lee Borthwick as CEO
